MedTrace Logo

Intravitreal Celecoxib for Chronic Uveitis

NCT02131012 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-02-23

No results posted yet for this study

Summary

Intraocular delivery of celecoxib will be an effective means to treat inflammation and macular edema and prevent structural complications and vision loss in patients with chronic inflammation or macular edema who are unable to tolerate corticosteroids due to their side effects.

Conditions

Interventions

DRUG

Intravitreal Celecoxib

1-4 mg intravitreal celecoxib

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Vanderbilt University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-11-01
Completion
2016-11-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131012 on ClinicalTrials.gov